In a clinical trial recently conducted has shown that a serum that contain cannabidiol was able to improve the appearance of facial skin on each of the participants. This clinical trial was based on the effects of CBD (cannabidiol) facial serum which went onto find a 100% overall improvement in the appearance of skin after only 2 weeks into the treatment.
CBD is described as a non-psychoactive and natural compound which is found in the flowers, stalks and seeds of the cannabis plants. These concentrations are higher in hemp in comparison to marijuana.
After the 1st week of treatment, 85.71% of the participants reported on improvements. After 14 days of the treatment this percentage increased to 100% in regards to noticing improvements. This trial also discovered that 80.95% of the participants noticed improvements in regards to the appearance of wrinkles and fine lines around the area of the mouth.
Research before this has also discovered that cannabinoids such as CBD has therapeutic values in regards to treating conditions such as acne and psoriasis. One of the patents by the USNIH (U.S. National Institutes of Health) has shown that CBD contains important neuroprotective and antioxidant properties. However, CBD is still not received FDA approval for treating any condition. At Chiropractor Eagle Idaho The use of Natural Pain product like CBD Pain Rubs is possible to help patients achieve better health.
If CBD has been infused into a topical product which comes from industrial based hemp which does not include marijuana, it is legal for purchase in any of the states across the U.S. Recent reports from the Hemp Association has discovered that the hemp CBD products has accounted for around $65 million out of the $573 around 11% of the total retail sales of industrial hemp throughout the U.S. in the year 2015.
AXIM® Biotechnologies, Inc which is an investment company to Medical Marijuana, Inc is in the process of conducting clinical trials in order to study effects of topical infused with cannabinoids for skin conditions that include eczema and psoriasis.
The condition known as psoriasis is described as a type of autoimmune disease which results in the rapid accumulation of skin cells on the surface of the skin creating white scales, red and raised plaques. According to the IFPA ( Federation of Psoriasis Associations) there are around 150,000 new cases that are reported each year in the U.S. Atopic dermatitis or eczema is linked with inflammation which results in dry, red and itchy skin. Around 31.6 million individuals have these symptoms in the U.S. which is information supplied by the National Eczema Association.
The AXIM®’s concept trial to prove the effects of cannabinoids involved testing ointments which contain another important cannabinoid in cannabis known as CBG (cannabigerol). Similar to CBD, CBG is also non-psychoactive and also found in higher levels in hemp compared to marijuana. The earlier research has gone onto suggest that CBG is known for its anti-inflammatory properties and can be useful to inhibit tumor growths and the treatment of glaucoma.
To date, CBG has not been studied as well when compared to CBD, but it is still a highly interesting molecule is what Dr. George Anastassov chief-executive officer from AXIM told Forbes earlier on in the year. These latest trials will be overseen by Dr. Marcus Meinardi at The Maurits Clinic based in Hague in the Netherlands. In these studies a group will receive treatment using the CBG oil, while another group will be given the placebo, while a 3rd group with be given a “gum” product that contains CBG. This trial is in place to examine the anti-inflammatory properties of CBG-based ointments.